About
Diabetes Free, Inc. develops antibody-based therapies targeting CD20 and CD40 to treat autoimmune diseases including multiple sclerosis and rheumatoid arthritis, as well as oncology indications.
Explore Diabetes Free's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.